الفهرس 
ntroduction And aim of workيوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 102 |  |  |
| | | from | 102 | | |
المستخلص
Ovarian cancer is a common malignant gynecological tumor that is difficult to diagnose early, progresses rapidly, and causes high mortality. Each year, 238,700 new ovarian cancer cases are diagnosed worldwide with 151,900 patient deaths (Ferlay, J et al. 2015). Approximately 90% of ovarian cancers are epithelial malignancies in terms of histological type and other rare histological types (Coburn, S.B. et al. 2017). Among all gynecological tumors, ovarian cancer has the highest mortality rate and the worst prognosis. Approximately 70% of ovarian cancers develop into advanced cancer upon discovery. Although surgical treatment, chemotherapy, radiotherapy, and targeted therapy have developed rapidly in recent years, the 5-year survival for patients with ovarian cancer is only 20% (Cortez, A.J. et al 2018 and Mallen, A. et al. 2018). Therefore, new ovarian cancer markers are urgently needed to detect early recurrence and poor prognosis. The aim of the present study was to investigate the prognostic value of p53 expression in tumor samples from 50 patients with serous epithelial ovarian cancer as well as different traditional prognostic factors. P53 CORRELATION WITH PATIENT AND DISEASE charACTERISTICS. Age The correlation between P53 expressions with age had been previously explored in number of studies. In our study we found no significant association between P53 expression with the age (P 0.05). Our results was in agree with that reported by Ndukwe CO et al., 2018 and de Graeff, P., et al. 2006. Ndukwe CO et al., 2018 in their study on 50 patients with epithelial ovarian cancer patients revealed that P53 expression was more common in those above 50 years of age, yet no association was found between p53 expression and age of patient. However, there was a statistically significant association between p53 positivity and tumor grade (P < 0.01), histologic subtype (P = 0.009) and molecular subtype (P < 0.01), with p53 positivity being more common in high-grade EOC, serous tumors, and Type 2 EOC.